OCTREOTIDE ACETATE PRESERVATIVE FREE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for OCTREOTIDE ACETATE PRESERVATIVE FREE (OCTREOTIDE ACETATE PRESERVATIVE FREE).
Octreotide is a synthetic octapeptide analog of somatostatin with similar pharmacologic actions. It inhibits the secretion of growth hormone (GH), glucagon, and insulin. It suppresses luteinizing hormone (LH) response to gonadotropin-releasing hormone (GnRH), reduces splanchnic blood flow, and inhibits secretion of serotonin, gastrin, vasoactive intestinal peptide (VIP), secretin, motilin, and pancreatic polypeptide.
| Metabolism | Octreotide is primarily metabolized in the liver via the cytochrome P450 (CYP450) system, specifically CYP3A4, to water-soluble metabolites. Approximately 32% of the dose is excreted unchanged in the urine. |
| Excretion | Renal (approximately 32% unchanged) and biliary/fecal (approximately 55% as metabolites and unchanged drug). |
| Half-life | Terminal elimination half-life is approximately 1.5 hours after subcutaneous administration, with a longer terminal phase of 2-3 hours in acromegaly patients after intravenous bolus. |
| Protein binding | Approximately 65% bound to plasma proteins, primarily albumin and beta-lipoprotein. |
| Volume of Distribution | Approximately 0.2-0.3 L/kg, indicating distribution primarily in extracellular fluid. |
| Bioavailability | Subcutaneous: 100% (compared to intravenous). Intramuscular: 100% (when formulated as long-acting depot). |
| Onset of Action | Subcutaneous: Rapid; peak hormone suppression within 30 minutes. Intravenous: Immediate; within minutes. |
| Duration of Action | Subcutaneous: 6-12 hours for suppression of growth hormone and IGF-1; clinical effect may last up to 12 hours. Intravenous: 6-12 hours depending on dose and condition. |
Initial 50 mcg subcutaneously TID; titrate based on response. For carcinoid tumors, start 100-600 mcg/day subcutaneously in 2-4 divided doses. For acromegaly, initial 50 mcg subcutaneously TID, increase to 100-200 mcg TID. Intravenous dose (for carcinoid crisis): 100-500 mcg bolus IV, then 50-200 mcg/hour continuous IV infusion.
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment required for renal impairment; however, caution in severe renal failure (CrCl <10 mL/min) due to prolonged half-life. No formal GFR-based guidelines exist. |
| Liver impairment | No Child-Pugh based adjustments. In cirrhosis, half-life may be prolonged; use with caution. No specific dose reduction defined. |
| Pediatric use | Not FDA-approved for children. Limited data: In carcinoid tumors, 1-10 mcg/kg subcutaneously TID (max 1500 mcg/day). For acromegaly, no established pediatric dose. Use only if potential benefit outweighs risk. |
| Geriatric use | No specific dose adjustment; use lowest effective dose. Monitor renal function as elderly may have decreased creatinine clearance. Increase dosing interval if renal impairment present. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for OCTREOTIDE ACETATE PRESERVATIVE FREE (OCTREOTIDE ACETATE PRESERVATIVE FREE).
| Breastfeeding | Excretion into human milk is unknown but likely minimal due to high molecular weight. No published M/P ratio available. Octreotide is poorly absorbed orally, so infant exposure via breastfeeding is expected to be low. Use with caution, especially in preterm infants or those with gastrointestinal disorders. Consider monitoring infant for hypoglycemia or growth disturbances. |
| Teratogenic Risk | Pregnancy Category B. In animal studies, no evidence of teratogenicity at doses up to 30 times the human dose. There are no adequate and well-controlled studies in pregnant women. Octreotide crosses the placenta. Use during first trimester: limited data suggest no increased risk of major malformations; however, due to effects on growth hormone and IGF-1, theoretical risk of fetal growth restriction exists. Second and third trimesters: potential for fetal growth restriction secondary to maternal suppression of growth hormone; case reports of low birth weight. Risk of maternal hyperglycemia or hypoglycemia (due to effects on insulin/glucagon) may indirectly affect fetus. |
■ FDA Black Box Warning
There is no US FDA black box warning for octreotide acetate.
| Serious Effects |
["Hypersensitivity to octreotide or any component of the formulation"]
| Precautions | ["Cholelithiasis: Octreotide inhibits gallbladder contractility and decreases bile secretion, leading to gallstone formation; monitor gallbladder ultrasonography at 6-12 month intervals.","Hypoglycemia or hyperglycemia: May alter insulin, glucagon, and growth hormone secretion; monitor blood glucose levels.","Bradycardia and heart block: May cause sinus bradycardia, atrioventricular block, and other conduction abnormalities; use caution in patients with cardiac disease.","Thyroid function: May suppress TSH secretion; monitor thyroid function tests.","Renal impairment: Reduce dose in patients with severe renal failure (CrCl < 20 mL/min).","Carcinoid syndrome: May cause severe hypoglycemia or hyperglycemia; monitor glucose closely.","Pancreatitis: Rare reports of acute pancreatitis, especially in patients with biliary tract disease.","Immunogenicity: Antibodies to octreotide may develop but do not correlate with therapeutic response."] |
Loading safety data…
| Fetal Monitoring | Monitor maternal serum glucose (fasting and postprandial) to detect hyperglycemia or hypoglycemia. Assess fetal growth via ultrasound every 4-6 weeks during second and third trimesters due to potential growth restriction. Monitor maternal blood pressure and renal function (octreotide may affect splanchnic blood flow). In cases of acromegaly, monitor maternal growth hormone and IGF-1 levels to maintain lowest effective dose. |
| Fertility Effects | In acromegaly, octreotide may restore fertility by normalizing growth hormone and IGF-1 levels, which can improve ovulatory function. No direct adverse effects on fertility reported. However, suppression of gonadotropins may occur in some patients, potentially impacting sperm or oocyte quality; this is generally reversible upon discontinuation. |